Exosens share falls below all its moving averages and loses 2%
After two consecutive rebound sessions that had brought the Bordeaux-listed stock to the level of its long-term moving average, Exosens loses ground this Wednesday in a SBF 120 itself oriented downwards. The decline pushes the stock below all of its moving averages, in a technical configuration that warrants attention as the global geopolitical context remains tense.
A decline of nearly 2% that pushes the stock below its three moving averages
The Exosens share is down 1.96% in trading at €57.45, thereby erasing some of the ground gained during the two previous sessions. This move is all the more notable as the stock simultaneously falls below its MA20 (€60.61), its MA50 (€59.85) and its MA200 (€58.44), marking an erasure of all three technical benchmarks in a single stroke. The gap to the MA200 remains contained at 1.69%, but the configuration is less favourable than at Tuesday's close, when the stock had returned to the level of its long-term moving average.
The RSI at 47 remains in neutral territory, without any marked signal of selling exhaustion, which does not suggest an immediate rebound. The session is part of a generalised decline: the SBF 120 falls 1.72% and the CAC 40 declines 1.79%, in a European market weighed down by tensions over long-term rates and geopolitical uncertainties. The next identifiable support level stands at €55.20, approximately 3.9% below the current price.
A monthly balance still in negative territory despite a year of solid gains
Over one month, Exosens' decline reaches 9.17%, a significant correction that contrasts with performance over twelve months: the stock still shows +53.61% over a year, testifying to an intact long upward trajectory despite recent turbulence. Over the week, the change remains close to equilibrium (+0.52%), showing that pressure is concentrated over the past month rather than the last few days. Over three months, the decline is 6.13%, consistent with the consolidation dynamic observed since summer. On the fundamentals side, when publishing Q1 2026 results (27 April 2026), the company had highlighted the strengthening of commercial momentum in defence and the expansion of optronic technologies as growth drivers, while noting that rising geopolitical tensions and risks linked to production capacity expansion remained areas of concern.
The first BiNOD order from the U.S. Army obtained by its subsidiary Photonis Defense, announced at the end of August 2026, concretely illustrates this anchoring in the American defence market. The €55.20 support level now constitutes the next threshold to monitor in the event the decline continues.
